Novavax, Inc. (NASDAQ:NVAX) announced its financial results for the fourth quarter and twelve months ended December 31, 2016.
Novavax, Inc. (NASDAQ:NVAX) announced the initiation of a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F …
In a research report released Friday, FBR Capital analyst Vernon Bernardino reiterated an Outperform rating on shares of Novavax, Inc. (NASDAQ:NVAX), with a price …
Chardan is divided when it comes to forecasts moving forward for biotech stocks Novavax, Inc. (NASDAQ:NVAX) and Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR).
Novavax, Inc. (NASDAQ:NVAX) investors are clearly concerned today after the vaccine maker reported its third-quarter results and announced corporate restructuring plan.
Novavax, Inc. (NASDAQ:NVAX) announced its financial results for the third quarter and nine months ended September 30, 2016, in conjunction with its Investor …
On October 7th, Novavax, Inc. (NASDAQ:NVAX) announced that it had rescheduled its annual investor meeting from tomorrow, October 11th and moved it to …
Novavax, Inc. (NASDAQ:NVAX) announced it has rescheduled its 4th annual Investor and Analyst Meeting.
Chardan Capital analyst Keay Nakae is out today with a research note on shares of Novavax, Inc. (NASDAQ:NVAX), reiterating a Neutral rating, while slashing the price …
Analysts are weighing in on Novavax, Inc. (NASDAQ:NVAX) and XOMA Corp (NASDAQ:XOMA), as shares of both companies fell sharply today due to various …
